Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Berthold Boedeker

Innovation in Bio-manufacturing: Disposables, Ballroom Plants and Continuous Processing

Bayer

Paul Denny-Gouldson

Bioprocess in the Millenial Age

IDBS, UK

Showing of Streams
10:30 - 11:10

Morning Coffee and Networking

Showing of Streams
12:40 - 13:40

Lunch in the Exhibition Hall

Showing of Streams
15:40 - 16:10

Afternoon Coffee

Showing of Streams
16:50 - 16:55
Closing Remarks from the Chair and End of Bioproduction 2017

Closing Remarks from the Chair and End of Bioproduction 2017

08:50 - 09:00 10 mins
Plenary Session
Chairperson's Opening Remarks
  • Barak Barnoon - Director Process Engineering, Bristol-Myers Squibb
more
09:00 - 09:30 30 mins
Plenary Session
Innovation in Bio-manufacturing: Disposables, Ballroom Plants and Continuous Processing
  • Berthold Boedeker - Chief Scientist and Project Coordination, Bayer
more

Recent developments in processing, equipment and plant design have substantially changed the way of biopharmaceutical production. By using disposable technologies, closed systems operation and continuous processing, small and flexible production plants are nowadays an attractive alternative the established large scale, hard piped facilities. Different aspects for such ball room plant based flexible set-ups will be discussed in combination with the benefits and limitations of using disposables and continuous processing.

09:30 - 10:00 30 mins
Plenary Session
BPOG Roadmap - Best Practice for Future Manufacturing Solutions
  • Morten Munk - Global Technology Partner, Global Best Practice, NNE, Denmark and Member of BPOG Technology Road Map Group
more
10:00 - 10:30 30 mins
Plenary Session
Bioprocess in the Millenial Age
  • Paul Denny-Gouldson - Vice President, Strategic Solutions, IDBS, UK
more

Bioprocess is a critical part of the NBE development cycle and over the past few years has become more and more standardised. In this talk we will discuss the foundational data management and reporting pieces required to support cell line development, fermentation scale up, purification optimisation and analytical testing. Coupled with process development data management and reporting are the requirements for integration with instrumentation and real time data acquisition systems. We will explore these topics and examine the business benefits in detail using customer case studies and real world evidence of what works and what doesn’t when planning, implementing and running a development to manufacturing process development data management platform.

10:30 - 11:10 40 mins
Morning Coffee and Networking
11:10 - 11:30 20 mins
Cell Culture & Upstream Process Development
Development and Scale Up of an Intensified Perfusion Process for Life Cycle Management
  • Jiuyi Lu - Senior Scientist, BioProcess Development, BioPharmaceutics Development, Sanofi
more

In support of life cycle management of a commercial product, we developed an integrated continuous process comprised of high-density perfusion cell culture directly coupled to a continuous capture step. This new process has similar product quality compared with 1st generation process with significantly increased productivity. Process robustness and consistency was dramatically improved as well. With computational fluid dynamics (CFD) simulation, process was successfully scaled up to commercial scale.

11:10 - 11:30 20 mins
Manufacturing Strategy & Technology
Steps Towards Standardisation and Interchangeability to Ensure Single Use Systems Supply Chain Security
  • Dave Wolton - Biopharma Technology Consultant, PM Group
more
  • Steps towards the standardisation of single use technologies e.g. standardised geometrics and connectors
  • Interchangeability and improving connectivity of single use systems
  • Ensuring supply chain security for critical equipment and single use components in commercial manufacturing
  • How to improve company internal organisation to ensue supply chain security
  • Interactions between vendors and pharma companies
  • Addressing the future challenges and equipment demands in the industry today
11:10 - 11:30 20 mins
Downstream Processing
Multiproduct Facilities: How to Use A 5m2 Footprint For All Downstream Processes At Clinical Scale
  • Oliver Fay - Project Manager, Mallinckrodt Pharmaceuticals Dublin
more
  • Design of an integrated utility, electrical & instrumentation panel, which can be used for all downstream processes
  • Electrical, Instrumentation and data connectivity strategy
  • CIP & SIP philosophy for skids and vessels, including minimising hazardous cleaning solutions interaction.
  • Benefits and Drawbacks
  • Future Design Possibilities. 
11:10 - 11:30 20 mins
Microbial Manufacturing
Technology Toolbox for the Production of Non-MAb Biotherapeutics in Microbial Systems
  • Stefan Krahulec - Senior Manager Technology & Innovation, Boehringer Ingelheim RCV GmbH & Co KG
more

Decreasing timelines for process development and increasing diversity of biotherapeutic drugs require modular, ready to use unit operations which can be combined to a robust and efficient manufacturing process. This is particularly true for the large diversity of molecules produced in microbial systems. To address this complexity, Boehringer Ingelheim Biopharma Austria has established toolbox elements across the entire process chain ranging from a modular vector concept to platform purification technologies for non-platform proteins.

11:30 - 11:50 20 mins
Cell Culture & Upstream Process Development
An Upstream Processing Development Case Study with a Focus on Early Stage Process Validation Activities
  • Chris Sadler - Senior Manager, Process Science, Allergan Biologics Ltd., an affiliate of Allergan plc
more

This presentation will cover the approach taken for the Process Design/Characterisation (Process Validation Stage 1) of a biological product in late stage process development. We will look at the importance of both historical data at production scale and the application of scale down models to determine process robustness prior to Process Qualification (Process Validation Stage 2).


11:30 - 11:50 20 mins
Manufacturing Strategy & Technology
Outsourcing the Development and Manufacturing of Biopharmaceuticals – Best Practices when Working with External Partners
  • Ulrich Rümenapp - Head of Launch Preparation and Coordination , Bayer, Germany
more
  • The drivers and benefits of outsourcing CMC development and biomanufacture
  • What to outsource and what to do in house?
  • What are the risks in outsourcing and how to mitigate those?
  • Selecting the right partner, good contract making and establishing an efficient partnership
11:30 - 11:50 20 mins
Downstream Processing
Novel Formats, Novel Resins
  • Christopher Teske - Principal Engineer, Genentech
more

In recent history biologics have become a more and more important option in treating severe disease. Mostly these biologics have been antibodies, and the pharmaceutical industry has developed powerful tools for the production these therapeutic modalities, e.g. affinity chromatography. At Roche, we have engaged in working more and more with new formats that can only to some extent be handled by these tools, as these novel formats may come with more product-related impurities, that are harder to remove.

Here we would like to present a case study on a particular molecule that did not fit the standard antibody purification platform. In order to develop a suitable purification process, we had to go search for new tools, and these were provided by Thermo Fisher as CaptureSelect FcXL. Introducing a novel raw material, especially if it is as crucial as a capture resin, is always a challenging tasks. In this presentation we would like to describe how joint efforts between Roche and Thermo Fisher led to a successful introduction of this novel resin into a 12K production campaign.

11:30 - 11:50 20 mins
Microbial Manufacturing
When Robots met Microbes!
  • Emilie Navarro - Microbial Process Development USP Supervisor, Merck Biodevelopment (Merck Kga), Martillac France
  • Christelle Sihabout - Microbial Process Development DSP Supervisor, Merck Biodevelopment (Merck Kga), Martillac France
more

Microbial production is composed by several units operations which need optimization to deliver robust processes. Whereas microbes are used since the dawn of time, innovative tools are critical to ensure reliable process definition. During this presentation, use of HTS robotic platforms across fermentation and purification will be discussed by highlighting their impressive capabilities for process and late stage developments.

11:50 - 12:10 20 mins
Cell Culture & Upstream Process Development
Development and Scale Up of the Cell Culture Harvest Process for Biopharmaceutical Production
  • Markus Brakel - Senior Scientist in Biopharmaceutical Cell Culture Development, Boehringer Ingelheim
more

The classical cell culture harvest process which is a current industry-standard is a combination of a cell separation followed by a depth- and membrane filtration cascade. The setup of the centrifuge, the choice of filters and the optimization of process parameters such as separator feed flow rate, inlet/outlet pressure in centrifuge, filtration flow rate, filter sizing as well as preparational and polishing steps (e.g. filter equilibration, flushing, and blow out) have a significant influence on the process performance, the product yield as well as product quality. The scale up of separation processes is performed based on scientific scale up criteria and standard procedures (e.g. constant Flux, ratio of Flow rate : equivalent clearance area = Q/Σ). The transfer of a cell culture harvest process is supported by a wide set of offline and online monitoring data. Process parameters such as Particle –size-distribution analysis, filtration flow/flux rates, pressure profiles and turbidity measurements create a solid data base for the evaluation and optimization of a harvest process. In recent years, new cell culture pretreatment/harvest strategies have been developed such as low pH precipitation, flocculation or diatomaceous earth filtration. The development of a single-use-harvest process is a different story. Here, the right choice of depth and membrane filters is key to a successful harvest process. My talk will focus on BI´s standard strategy for harvest development, scale up and transfer for traditional processes as well as for single use harvests. I will also give an overview about new technologies, filter designs and harvest strategies for upcoming high cell density processes.

11:50 - 12:10 20 mins
Manufacturing Strategy & Technology
Streamlining Process Risk Assessments from Early Development to Commercial Manufacturing
  • Uroš Gregorc - Senior Scientist, Process Development Strategy, Sandoz GmbH
more

Process risk assessment are at the heart of the enhanced approach to process development and very well established in biologics development but are still sometimes considered as complex and time consuming tasks. With harmonized approaches from early development to commercial manufacturing we have streamlined the efforts required to execute process risk assessment.

11:50 - 12:10 20 mins
Downstream Processing
Process Control Strategy for a Gene Therapy Product
  • Mark Plasvic - Chief Technology Officer, Lysogene
more
11:50 - 12:10 20 mins
Microbial Manufacturing
Bioprocess Development in the Age of Digitalisation: Intelligent Experiments as Key Component
  • Nicolas Cruz-Bournazou - PhD, Technische Universität Berlin
more

Advances in digitalisation bring a large number of possibilities to create, collect, store, and share data. This has a significant impact in biotechnology were the complexity of living organisms can be studied deeper and analysed by computers and experiments can be carried out by robotic stations fast and in a high degree of parallelization. Nevertheless, speaking of automation, control, and digitalization, the bioindustry is clearly behind other fields of engineering. The complexity of biological systems hampers an efficient use of computer aided tools. The substantial problem is that it is not possible to create a reliable mathematical model (digital twin) even of simple biological systems.  Changes in protein expression, metabolic activity, mutations, etc. cannot be foreseen, described, nor fully understood. This means that the internet of things in biotechnology will be always coupled with experimental activities to validate and re-adjust models to living systems.

These experiments need to be designed intelligently and carried out in miniaturized parallel Liquid Handling Stations (LHS). Existing engineering tools need to be further developed and adapted to fill this gap between the digital space and the experimental system. Methods for Design of Experiments (DoE) have been developed and widely applied to this end. Still, if we consider systems where the time dependent response is important (e.g. most engineering applications) the experimental design has to consider the nonlinear dynamics of the process. If this is the case, more advanced tools are required, namely methods for Optimal Experimental Design (OED). These methods have to be further developed aiming to i) design optimal dynamic experiments in very short time, ii) communicate with the robotic facility that preforms the experiment, iii) learn from the data as it is being generated, iv) re-fit the parameters of the model to the data, and v) re-design the optimal experimental strategy.

All these methods need to be integrated in a framework to create an intelligent laboratory for rapid characterization of biosystems including: easy interaction of all devices, experimental design programs tailored for robotic LHS, online optimization algorithms that enable an optimal operation of the robots, and advanced control methods to assure the correct operation of the facilities.

12:10 - 12:40 30 mins
Cell Culture & Upstream Process Development
Implementation of Various High Through-put Technologies for Accelerated Process Development of Biopharmaceuticals
  • Torben Frandsen - SVP Process Development and Technology Coordination, CMC Biologics
more
12:10 - 12:40 30 mins
Manufacturing Strategy & Technology
Selecting the Right MES Solution for Modern Biologics Manufacturing
  • Keith Bowen - General Manager, LZ Lifescience
more
12:10 - 12:40 30 mins
Downstream Processing
Evaluation of a Highly Alkali Stable Protein A Matrix for Improved Purification of Monoclonal Antibodies
  • Jonathan Royce - BioProcess Senior Product Manager, GE Healthcare
more

Historically, the alkali-stability of Protein A chromatography resins has lagged behind other resins used in downstream purification of antibody therapeutics. This fact, combined with the high nutrient load to which Protein A resins are exposed, introduces a larger risk of column contamination as compared with secondary and tertiary chromatographic steps. In this presentation, we present a newly designed Protein A resin, which offers alkali-stability on par with ion exchange and hydrophobic interaction chromatography resins. Data on binding capacity, caustic stability, and resin cleanability will be presented.

12:10 - 12:40 30 mins
Microbial Manufacturing
Bioprocess Scale Down Studies of Escherichia Coli based Inclusion
  • Peter Neubauer - Chair for Bioprocess Engineering, Berlin University of Technology (TU Berlin), Germany
more

Aside from the normal set of the 20 canonical amino acids, E. coli can also synthesize non-canonical amino acids, such as norvaline and norleucine. Their synthesis occurs under oscillating conditions as they occur in industrial scale bioreactors and is further increased when the target protein product has a high content of leucine, as in many of the commercial peptide products, which are normally produced as inclusion bodies. Under these circumstances these amino acids can be incorporated into the recombinant protein, which can be a problem in the industrial production of pharmaceutical proteins but may be interesting for the area of synthetic biology. Our studies show that the mixing time is a key parameter and that this issue can be studied in different scale down simulators.

12:40 - 13:40 60 mins
Lunch in the Exhibition Hall
13:40 - 14:10 30 mins
Cell Culture & Upstream Process Development
Rising Stars Poster Presentations
more

13:30-13:40 Poster 4: Implementing CRISPR/Cas9 targeting microRNAs in Chinese Hamster Ovary cells to improve bioprocess attributes

Kevin Kellner, PhD Student, National Institute for Cellular Biotechnology, Dublin City University, Ireland

13:40 – 13:50 Poster 3: Modification of transgene RNA secondary structure to improve translational output and improve protein yield in Chinese Hamster Ovary Cells

Alan Costello, PhD Student, National Institute for Cellular Biotechnology, Dublin City University, Ireland

13:50-14:00 Poster 1: Using miRNA and proteomic profiling to identify targets involved in proteolysis of recombinant fusion proteins,and using LC-MS-MS techniques to characterise the effect proteolysis has on the quality of the fusion protein product

Laura Bryan, PhD student, NICB, Dublin City University, Ireland

14:00-14:10 Poster 6: miRNA-based genetic switches to modulate transgene expression in CHO cells

Ricardo Valdes-Bango Curell,Marie Curie Early Stage Researcher / PhD Student, National Institute for Cellular Biotechnology, DCU, Ireland


13:40 - 14:10 30 mins
Manufacturing Strategy & Technology
Poster Presentations: Cutting Edge Developments in Biomanufacturing Strategy and Technology
more

13:40-13:50 Poster 5 - Rising Star: Leachables from single-use disposable bioreactors and their toxicity to Chinese hamster ovary (CHO) cells

Paul Kelly, Postdoctoral Research Scientist, National Institute for Cellular Biotechnology, Ireland

13:50-14:00 Poster 8: Antibody Affinity Extraction(AAE) – A Superior Alternative To 2D Western Blot

Eric Bishop, VP of Research and Development, Cygnus Technologies

13:40 - 14:10 30 mins
Downstream Processing
Poster Presentations: Cutting Edge Developments in Downstream Processing
more

13:40-13:50 Poster 23: CO2 Gas Permeation and pH Stability in Single-use Bags

Mike Johnson, Business Development Engineering Manager, Life Sciences, Entegris

13:40 - 14:10 30 mins
Microbial Manufacturing
Poster Presentations: Cutting Edge Developments in Microbial Manufacturing
more

13:40-13:50 Poster 7: A Novel Online Glucose Monitoring Tool for the Characterisation of an Anthrax Vaccine Upstream Process

Williams C. Olughu, Senior Scientist Fermentation, Porton Biopharma Limited

13:50-14:00 Poster 2 - Rising Star: Towards extracellular secretion of recombinant proteins using antisense technology 

Shahin Heshmatifar, PhD student, UCL, UK

14:00-14:10 Poster 13: Process intensification with 3M filters for E. colibased recombinant protein production

Michael Maurer, Research Division Bioengineering, University of Applied Sciences Campus Vienna

14:10 - 14:30 20 mins
Cell Culture & Upstream Process Development
A Case Study on mAb Product Optimisation
  • Mustafa Alam - TS/MS Lab Representative, Eli Lilly
more
14:10 - 14:30 20 mins
Manufacturing Strategy & Technology
Management of Post-Approval Changes for Rapidly Growing Biologics: Regulatory and Supply Considerations
  • Brian Mullan - Head, Manufacturing Science and Technology, Novartis
more
14:10 - 14:30 20 mins
Downstream Processing
FcRn Affinity Column Chromatography for Therapeutic mAb Characterisation
  • Tilman Schlothauer - Senior Principal Scientist, Roche Innovation Center
more

Fc receptor based affinity chromatography is a new emerging field of Fc functionality analytics. Until now different human FcγReceptors (FcγRIIIa & IIa) and the Fc Receptor neonatal (FcRn) from three species have been utilized for coupling onto Sepharose based matrices. FcRn affinity columns separate antibody species (analytical and preparative) that differ in their affinity to FcRn receptors using conditions that closely resemble the physiological mechanism of interaction between IgG and FcRn. This opens the possibility to easily assess and design FcRn-mediated pharmacokinetic properties of new antibodies, new Ab formats and Fc fusion proteins. Utilizing FcRn affinity columns also allows the analysis of the functional impact of Ab Fc degradation events like oxidation with respect to FcRn receptor binding.

14:10 - 14:30 20 mins
Microbial Manufacturing
Overcoming the Problems of Implementing Single-Use Systems in Legacy Microbial Processes
  • Ying Gao - Technical Support Specialist, Porton Biopharma Ltd
more
  • Industry case study on implementation of single-use technologies in legacy microbial production
  • Overcoming the problems of application single-use technologies for microbial processes, e.g. process development and characterisation, regulatory requirement, Extractables and Leachables, etc.
  • Scale up approaches and process validation for disposable implementation
14:30 - 14:50 20 mins
Cell Culture & Upstream Process Development
Bioreactor Scale Up Considerations
  • Fiona Madden - Senior Associate Scientist, Janssen Biologics
more

Scaling up of fed batch bioreactor processes from lab bench top scale to clinical and commercial production scales can be challenging. We have looked at a number of process engineering points to consider when scaling up to ensure bioreactor success right first time.

14:30 - 14:50 20 mins
Manufacturing Strategy & Technology
TELECONFERENCE: Implementation of Disposables in Mammalian Production and Adaption for Application in Microbial Production
  • Adriana Kiędzierska-Mencfeld - Head of Production Department, Polpharma Biolgics, Poland
more

This presentation will take place in: Liffey Meeting Room 1

14:30 - 14:50 20 mins
Downstream Processing
Robust Sensors and Adsorbents for Biomanufacturing
  • Kal Karim - Senior Lecturer in Organic and Computational Chemistry, University of Leicester
more

This contribution highlights some of the technologies developed at Leicester University in collaboration with clients in the pharmaceutical industry manufacturing sector for process monitoring and control. The overview will encompass methods for cleaning verification of plant and equipment, monitoring of residual genotoxic impurities in product streams, measurement of particle-particle and particle-surface interactions in formulation quality control and the development of molecularly imprinted polymer (MIP)-based sensors for selective analyte monitoring.

14:30 - 14:50 20 mins
Microbial Manufacturing
TELECONFERENCE: Implementation of Disposables in Mammalian Production and Adaption for Application in Microbial Production
  • Adriana Kiędzierska-Mencfeld - Head of Production Department, Polpharma Biolgics, Poland
more
14:50 - 15:10 20 mins
Cell Culture & Upstream Process Development
Potential and Limits for Controlling Glycosylation by Media Composition and Process Parameters
  • Martin Jordan - Associate Manager, Merck Serono
more

The development of biosimilars as well as the recent progress of analytical methods stimulated the search for factors influencing the glycosylation and provided new tools to modulate the quality recombinant proteins. The potential and the limitations of such tools for both biosimilars and novel proteins to tailor and to control the product quality will be discussed.

14:50 - 15:10 20 mins
Manufacturing Strategy & Technology
Advocacy Efforts in Response to Anticipated REACh Regulation on Triton X-100
  • Marie Murphy - Microbiologist, Biotechnology Operations , Eli Lilly and Company, Ireland
more

In conjunction with European Federation of Pharmaceutical Industries and Associations (EFPIA) and other key industry consortia, Eli Lilly & Company has been playing a critical role in the advocacy efforts undertaken within Europe to highlight the potential impact of REACh authorization for Triton X-100. In this presentation, we will provide an update on the current status of the proposed Annex XIV candidate listing for 4-tert-OPnEO, along with possible options to mitigate long term impact should this viral inactivation agent be eventually restricted for use within the EU.

14:50 - 15:10 20 mins
Downstream Processing
A Rational Approach for Process Design of Protein Conjugation
  • Roger-Marc Nicoud - Founder & CEO, Ypso-Facto, France
more
15:10 - 15:40 30 mins
Cell Culture & Upstream Process Development
Case Study: How a Custom Single Use Bioreactor Design Provides Seamless Process Transfer to Commercial Production
  • Paul Kubera - Vice President, Process Technology, ABEC, Inc.
more
  • Applying bioreactor modeling to process scaling
  • Characterizing baseline mass transfer and blend time performance
  • Development of a clear path for rapid 10x scale-up and transfer between multi-use stainless steel and single use
15:10 - 15:40 30 mins
Manufacturing Strategy & Technology
Ramping-up to Maximum Plant Capacity in a Biotech Facility Using Simulation and Scheduling Tools
  • Anna Marya Jobe - Project Lead, BioPlant Operations, UCB Farchim SA
more

Very shortly after the start-up of our Biotech plant at UCB (Bulle, Switzerland), we were faced with the challenge of ramping-up our production rate to meet increasing market demands. A simulation tool from Bio-G was used to verify our maximum plant capacity and to ensure seamless running with several bottleneck resources. Thus, we confirmed that the maximum run rate of the plant was ~10% lower than the theoretical maximum capacity established during the design phase. Using Bio-G’s scheduling tool to coordinate multiple activities amongst various departments, we were able to sustain this rate over a long period of time.

15:10 - 15:40 30 mins
Downstream Processing
Scalability of Planova™ BioEX Processes
  • Bixente Martirene - General Account Manager Europe, Asahi Kasei Bioprocess
more
  • Correspondence between small-scale filtration data and manufacturing-scale filter performance is absolutely critical to predict manufacturing process performance from small-scale viral clearance validation studies.
  • In this study on Planova BioEX filters, hollow fibers from three different lots were manufactured into filters having effective surface area ranging from 0.0003 m2 to 4.0 m2.
  • All the filters were evaluated for flux performances and for viral clearance capability using PP7 bacteriophage as a model for small virus contaminants.
15:10 - 15:40 30 mins
Microbial Manufacturing
Design of Novel Pichia Pastoris Promoters with High Performance in Fed-Batch
  • Diethard Mattanovich - Professor, University of Natural Resources and Life Sciences Vienna (BOKU)
more

Traditionally, Pichia pastoris has mainly been used for recombinant protein production with its methanol regulated AOX1 promoter. However, the use of methanol in large scale poses technological drawbacks and safety issues. To overcome these, we have designed new promoter systems which fit ideally to glucose limited fed-batch processes, finally outperforming the methanol driven expression system.

15:40 - 16:10 30 mins
Afternoon Coffee
16:10 - 16:30 20 mins
Cell Culture & Upstream Process Development
High-Yield, Mineral Medium, Antibiotics Free E. Coli Expression System
  • Christoph Reese - Director Microbial Fermentation, Roche Diagnostics GmbH, Germany
more

The development of a mineral medium based, antibiotics free E. coli expression system will be presented. In a case study, we show the suitability of the expression system for the manufacturing of a recombinant enzyme in industrial scale in high yield. The system may also be utilized to express otherwise insoluble proteins. A comparison to antibiotics-based selection systems and hydrolysates-based growth media will be discussed.

16:10 - 16:30 20 mins
Manufacturing Strategy & Technology
Global Particle Library for Drug Product Inspection
  • Adrian Bennis - Principal Engineer, Amgen
more
16:10 - 16:30 20 mins
Downstream Processing
Developing Models for Protein Solubility and Aggregation in Bioprocessing
  • Jim Warwicker - Reader, Manchester University
more

Although basic biochemistry tells us about the basis of protein solubility, e.g. charge versus hydrophobicity, it is harder to gather sufficient detail of the balance of interactions required for predictive models. In collaborative work, we have been looking at the available data that allow us to make such models, and make them available to the community via web tools.

16:10 - 16:30 20 mins
Microbial Manufacturing
High-Yield, Mineral Medium, Antibiotics Free E. Coli Expression System
  • Christoph Reese - Director Microbial Fermentation, Roche Diagnostics GmbH, Germany
more

The development of a mineral medium based, antibiotics free E. coli expression system will be presented. In a case study, we show the suitability of the expression system for the manufacturing of a recombinant enzyme in industrial scale in high yield. The system may also be utilized to express otherwise insoluble proteins. A comparison to antibiotics-based selection systems and hydrolysates-based growth media will be discussed.

This presentation will take place in: Liffey Meeting Room 3

16:30 - 16:50 20 mins
Cell Culture & Upstream Process Development
Digitalisation Platform and Supervisory Control of A Continuous Integrated Bioprocess Using Raman Spectroscopy
  • Michael Sokolov - Postdoctoral Fellow and Lecturer, ETH Zurich
more

The presentation uses the highly complex continuous integrated bioprocesses to show the potential of digital solutions for online process monitoring and control. A particular focus will be put on the different technological solutions which have to be integrated into a digital process system including IT platforms, process model solutions as well as advanced online sensors.

16:30 - 16:50 20 mins
Manufacturing Strategy & Technology
End of Bioproduction 2017
16:30 - 16:50 20 mins
Downstream Processing
Digitalisation Platform and Supervisory Control of A Continuous Integrated Bioprocess Using Raman Spectroscopy
  • Michael Sokolov - Postdoctoral Fellow and Lecturer, ETH Zurich
more

The presentation uses the highly complex continuous integrated bioprocesses to show the potential of digital solutions for online process monitoring and control. A particular focus will be put on the different technological solutions which have to be integrated into a digital process system including IT platforms, process model solutions as well as advanced online sensors.

This presentation will take place in: Liffey Meeting Room 3

16:50 - 16:55 5 mins
Closing Remarks from the Chair and End of Bioproduction 2017